4D-110
/ 4D Molecular Therap, Roche
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 22, 2025
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
(clinicaltrials.gov)
- P1 | N=13 | Active, not recruiting | Sponsor: 4D Molecular Therapeutics | Trial completion date: Jun 2027 ➔ Aug 2027 | Trial primary completion date: Jun 2024 ➔ May 2027
Trial completion date • Trial primary completion date • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders
January 19, 2023
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
(clinicaltrials.gov)
- P1 | N=13 | Active, not recruiting | Sponsor: 4D Molecular Therapeutics | Recruiting ➔ Active, not recruiting | Trial completion date: May 2023 ➔ Jun 2027 | Trial primary completion date: Nov 2021 ➔ Jun 2024
Enrollment closed • Trial completion date • Trial primary completion date • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders
July 23, 2020
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
(clinicaltrials.gov)
- P1; N=15; Recruiting; Sponsor: 4D Molecular Therapeutics
Clinical • New P1 trial • Gene Therapies • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders
1 to 3
Of
3
Go to page
1